Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil

T M Sievers1, S J Rossi, R M Ghobrial

  • 1Department of Surgery, Center for Liver Diseases and Transplantation, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Pharmacotherapy
|December 17, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Wire-loop lesion is associated with serological immune abnormality, but not renal prognosis, in lupus nephritis.

Lupus·2020
Same author

Transplantation for Hepatocellular Carcinoma: Is There a Tumor Size Limit?

Transplantation proceedings·2018
Same author

Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018
Same author

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.

Oncoimmunology·2018
Same author

Treatment of Refractory Gastrointestinal Bleeding in Patients With Portal Hypertension: A Case Series and Treatment Algorithm.

Transplantation proceedings·2017
Same author

Graft-Infiltrating Macrophages Adopt an M2 Phenotype and Are Inhibited by Purinergic Receptor P2X7 Antagonist in Chronic Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Mycophenolate mofetil, an immunosuppressant, prevents organ transplant rejection by inhibiting lymphocyte proliferation. It is approved for kidney transplants and shows promise for treating various refractory and chronic transplant rejections.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Mycophenolate mofetil is a prodrug of mycophenolic acid.
  • Mycophenolic acid inhibits lymphocyte proliferation by targeting inosine monophosphate dehydrogenase.
  • This enzyme is crucial for the de novo synthesis of guanine nucleotides.

Purpose of the Study:

  • To summarize the role and efficacy of mycophenolate mofetil in organ transplantation.
  • To highlight its current approved indication and potential therapeutic applications.

Main Methods:

  • Review of existing studies on mycophenolate mofetil in transplantation.
  • Analysis of its mechanism of action and clinical outcomes.

Main Results:

Related Experiment Videos

  • Mycophenolate mofetil is approved for preventing acute renal allograft rejection with cyclosporine and steroids.
  • Studies show efficacy in treating refractory rejection in renal, heart, and liver transplants.
  • Potential efficacy in managing chronic transplant rejection is suggested.

Conclusions:

  • Mycophenolate mofetil is a valuable immunosuppressant for preventing and treating transplant rejection.
  • Its mechanism of action provides a basis for its broad applicability in various transplant settings.